• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Redx Pharma, Pierre Fabre Laboratories to collaborate on cancer research

Redx Pharma, Pierre Fabre Laboratories to collaborate on cancer research

March 7, 2014
CenterWatch Staff

Redx, a provider of translational research capacity and experience in cancer stem cells, tumor immunology and anti-microbial resistance, and Pierre Fabre Research Institute (IRPF) have formed an agreement for cancer research. The exclusive deal will see Redx and IRPF work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.

Financial terms have not been disclosed, but Redx Pharma chief executive Neil Murray described the deal as a highly significant milestone in the company's development.

The Redx Pharma group is focused on early stage drug discovery and development programs at sites in Liverpool (Redx Oncology) and at Alderley Park, Cheshire (Redx Anti-Infectives).

Pierre Fabre, a French pharmaceutical company, has experience in both oncology and dermatology. Its portfolio focuses on chemotherapies, monoclonal antibodies, immuno-conjugates assets at various development phases and several value-added dermatological drugs, including dedicated products for orphan and debilitating conditions such as infantile hemangiomas. The pipeline has been reinforced recently with a licensing agreement for a new cancer therapeutic in immuno-oncology, AUNP12, an immune checkpoint modulator targeting the PD-1 pathway.

Neil Murray, chief executive of Redx Pharma, said, “The collaboration demonstrates the potential of our oncology pipeline to deliver novel cancer therapeutics which all concerned hope will generate significant patient benefits.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing